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A Double-Blind TVial of Protriptyline in the TVeatment of Sleep 
Apnea Syndrome 
Edward J. Stepanski, PhD,* William A. Conway, MD,+ David K. Young, MD,' 
Frank J. Zorick, MD,* Robert M. Wittig, MD,* and Thomas Roth, PhD* 
Eight male subjects with sleep apnea syndrome were given placebo and protriptyline in a double-blind 
crossover design to evaluate the effects of protriptyline on respiration during sleep. Treatment with 
protriptyline produced significantly better oxygenation and significantly fewer arousals during sleep, 
but sleep staging was unchanged. The decreased number of respiratory events approached 
significance and was much greater in six of eight subjects. A rapid eye movement sleep-suppression 
explanation of the improvement in oxygenation is not .supported. Alternative explanations of these 
findings are discussed. (Henry Ford Hosp MedJ 1988:36:5-8) 
Obstmctive sleep apnea is characterized by episodes of upper airway obstruction which prevent airflow during sleep. 
Hypersomnolence and cardiovascular changes, including pre-
cipitous decreases in blood hemoglobin oxygen saturation, ele-
vated PCO,, and marked cardiac arrhythmias, are associated 
with chronic sleep apnea syndrome. Despite these abnormalities 
in sleep-related respiratory function, most patients with this dis-
order have normal respiration during wakefulness (1). 
Treatments for obstructive sleep apnea are surgery or nasal 
continuous positive airway pressure (CPAP). Surgical treatment 
consists of tracheostomy and more recently uvulopalatophar-
yngoplasty (UPPP). Tracheostomy, while completely effective, 
is subject to both medical and psychological complications. 
UPPP has been shown to be effecrive only in a selected sub-
group of patients with sleep apnea syndrome (2,3). Generally, 
these procedures are indicated in cases of severe sleep apnea 
syndrome. The development of nasal CPAP as a treatment for 
apneic episodes is an altemative in patients with moderate to se-
vere apnea but is not well tolerated in all patients, particularly in 
those with mild apnea. Other treatment options, particularly for 
those patients with mild to moderate apnea, are needed. 
ProtriptyUne is a tricyclic antidepressant which has a side effect 
profile similar to other tricyclic dmgs, except that protriptyline is 
nonsedating. Several studies have suggested that treatment with 
protriptyline may improve obstmctive apnea (4-7). The reported 
degree of success varies in these studies, as does the experimental 
methodology employed. Two uncontrolled studies reported sus-
tained improvements in frequency and duration of apneic episodes 
in 57% (8/14) and 44% (4/9) of the patients treated with pro-
triptyline (4,5). Daytime hypersomnolence was also reported to 
improve. In both studies, the patients with less severe apnea (as de-
termined by number of events) were more likely to respond than 
those with severe apnea. 
The only controlled study (6) used a double-blind crossover 
design (placebo/dmg) to assess treatment in five male subjects 
with moderate apnea. These authors reported significant im-
provement in measures of oxygenation which were attributed to 
the rapid eye movement (REM) sleep-suppressing effect of pro-
triptyline. Obstmctive apneas in REM sleep are longer and have 
greater oxygen desaturation than non-REM sleep apneas, and 
thus overall oxygenation values improve when the number of 
REM events decreases significantly, even though no change oc-
curs in the total number of events. Another study (7) also sug-
gests that decreased REM sleep is the mechanism which leads to 
better oxygenation during the night in patients with apnea. Fur-
ther, during non-REM sleep, many apneic episodes became 
hypopneic episodes which also contributed to less hypoxemia 
in these patients. 
The present study was undertaken to study under controlled 
conditions the effects of treatment with protriptyline in a popu-
lation of patients having mild to moderate apnea. 
Methods 
The study included eight male subjects, aged 31 to 54 (mean 
44.9 ± 7.8 years), with obstmctive sleep apnea. These subjects 
were selected if they complained of daytime sleepiness and had 
an apnea index of at least 10. The average sleep onset latency 
across naps from the Multiple Sleep Latency Test (MSLT) was 
5.3 ± 2.5 minutes. All subjects were obese with ideal body 
weight ranging from 124% to 187%. Six subjects had essential 
hypertension, and three were diagnosed as having chronic 
obstmctive pulmonary disease. Two subjects had more serious 
Submitted for publicauon: November 10, 1987. 
Accepted for publication: January 6. 1988. 
*Sleep Disorders Center. Henry Ford Hospital. 
tDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, 
Henry Ford Hospital. 
Address correspondence to Dr Stepanski. Sleep Disorders Center. Henry Ford Hospital, 
2921 W Grand Blvd, Deuoit. Ml 48202. 
Henry Ford Hosp Med J—Vol 36, No 1. 1988 Sleep Apnea Syndrome—Stepanski et al 5 
Table 1 
Means and Standard Deviations of Sleep Parameters 
TST 
(min) SE %1 %2 %REM 
LAT2 
(min) 
LAT 
REM 
(min) 
WDS 
(min) 
AAR/ 
HR-TST 
Placebo 
Mean 403.3 83.0 54.2 33.8 10.3 20.0* 85.6* 75.8 72.6t 
SD 72.4 12.4 20.2 15.4 7.2 38.3 43.1 56.8 13.9 
Protriptyline 
Mean 424.6 86.7 57.8 34.2 6.9 26.8 164.5 60.6 40.7 
SD 42.7 8.3 18.1 15.5 5.2 39.7 76.1 42.6 13.6 
*P < 0.05 
tP < 0.01 
TST = total sleep time, SE = sleep efficiency, %1 = 
eye movement, LAT2 = latency to stage 2, LAT REM 
- arousal associated with respiration per hour of TST. 
percent stage 1, %2 = percent stage 2, %REM — percent stage rapid 
= latency to stage REM, WDS = wake during sleep, and AAR/HR-TST 
problems: one had chronic renal failure and received treatment 
with dialysis three times each week, and another had a history of 
congestive heart failure. Medications aside from the study drug 
were used by five subjects and consisted primarily of diuretics. 
Bronchodilators were used by two subjects and antihypertensive 
drugs by two others. 
The initial evaluation included a physical examination, a sleep 
history, clinical polysomnography (CPSG), and a MSLT. Polysom-
nograms consisted of five channels with standard placements for 
continuous monitoring of the central (C3) and occipital (OZ) 
EEGs, the horizontal electrooculogram, and the submental elec-
tromyogram (8). A V5 ECG lead was used to monitor heart rate. An 
additional four channels of respiratory recordings included nasal 
and oral airflow, diaphragmatic respiratory effort, and blood oxy-
gen saturation measured by a Hewlett-Packard ear oximeter. Sleep 
stages were scored according to standard criteria (8). 
A double-blind placebo-controlled crossover design with two 
treatment conditions was used. Subjects were randomly as-
signed to one of the two sequences (placebo first or drug first). 
Identical 10 mg capsules of placebo or protriptyline were admin-
istered for three weeks. After ten days of each drug treatment, 
each subject was interviewed to assess compliance with the pro-
tocol and the subjective degree of respon.se. Ifno subjective im-
provement in symptoms was observed, the dosage was increased 
to 20 mg. Half the subjects received increased dosages of pro-
triptyline, and 75% received increased dosages of placebo. 
After three weeks of nightiy administration, the outcome eval-
uation which included a nocturnal CPSG and subjective ratings 
of daytime sleepiness was performed. Arterial blood gases were 
obtained and ventilatory response to hypercapnia was measured 
the following day. Protriptyline blood levels were tested at the 
end of each three-week trial to assess compliance with the 
respective drug regimens. The second drug trial was initiated 
immediately following completion ofthe first trial. The entire 
protocol was completed in six weeks for each subject. 
Results 
Analysis 
Mean values from each group for each parameter were com-
pared with matched groups / tests. Criterion for significance was 
.set at P = 0.05. 
Sleep parameters 
Most sleep parameters were nearly identical on both drug and 
placebo (Table 1). The REM-suppression effect of protriptyline 
was evident as REM latency increased significantly (r = 2.69, 
P < 0.05). Stage REM as a percentage of total sleep time de-
creased from 10.3 to 6.9. Latency to stage 2 sleep was sig-
nificantly longer (t = 2.69; P < 0.05) with protriptyline as 
compared to placebo. Sleep fragmentation, measured by the 
number of arousals associated with respiration per hour of sleep, 
showed a significant improvement (t = 3.77, P < 0.01) from a 
mean of 72.6 to 40.7 with administration of protriptyline. This 
improvement was not reflected in percentage stage 1 sleep, 
which remained unchanged for the group as a whole. 
Respiratory parameters 
Oxygenation during sleep was significantly improved as 
measured by the number of minutes below 85% saturation (t = 
2.72, P < 0.05) (Table 2). Frequency of apneic episodes de-
creased from 44.4 events per hour of sleep with placebo to 36.7 
events with protriptyline, but this difference was not significant. 
The number of apneic episodes in REM or in non-REM sleep 
did not change significantly. Six subjects had a lower apnea 
index (mean reduction = 33%), while the remaining two wors-
ened. Respiratory events (apneic and hypopneic episodes com-
bined) per hour of sleep decreased from 87.3 to 65.7, which 
approached significance (t = 2.22, P < 0.06). All subjects had 
fewer respiratory events in the protriptyline condition with a 
mean reduction of 22% (range 2.5% to 71%). 
Pulmonary functions 
Waking blood gases revealed that arterial oxygen increased 
from 75 to 80 mm Hg with dmg administration, but this change 
was not statistically significant (Table 3). Arterial carbon diox-
ide decreased in five subjects and was identical in two others. 
There was a trend toward reduced PaCO, with protriptyline (t = 
2.03, P < 0.10). 
Subjective sleepiness 
Five subjects rated their daytime sleepiness as improved on 
protriptyline as compared to placebo. The remaining subjects 
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rated the two conditions equivalently, with two subjects feeling 
that neither treatment was helpful. 
Discussion 
The major finding from this study was the improvement in 
oxygen saturation during sleep with protriptyline administra-
tion. Subjects had significantly fewer EEG arousals associated 
with respiratory events. This finding is important as arousals 
have been shown to predict daytime sleepiness in patients with 
apnea (9,10). Daytime measures of sleepiness (MSLT) were not 
obtained, but nocturnal latency to stage 2 increased signifi-
cantly, and improvement of sleepiness occurred subjectively in 
six subjects. 
Previous studies have also reported that oxygenation im-
proves in patients with apnea who take protriptyline. In the pres-
ent study, this effect cannot be attributed to REM-suppression, 
as suggested by Brownell et al (6). Our subjects had low levels of 
REM in the placebo condition, and this did not decrease signifi-
cantiy during the protriptyline trial. In fact, the total REM time 
decreased by an average of only 11.8 minutes. The stability of 
several other measures also argues against REM suppression as 
an explanation of these data. For example, the number of apneic 
episodes during REM sleep, the average duration of apneic epi-
sodes, or the duration of the longest apneic episode should be 
significantly decreased if fewer apneic episodes during REM 
sleep were responsible for the improved oxygenation. 
A possible mechanism through which protriptyline improves 
oxygen saturation was suggested by a recent study on upper air-
way respiratory motor activity (11). Those authors found that 
protriptyline enhanced respiratory activity of the hypoglossal 
and recurrent laryngeal nerves. Since the hypoglossal nerve in-
nervates the genioglossal muscle, protriptyline acts to maintain 
the patency of the oropharyngeal airway. Increased muscle tone 
of the airway, particularly in the oropharynx, might lead to a re-
duction in the degree of obstruction and subsequently in the 
number of obstructive events. Smith et al (7) reported that ap-
neic episodes are more likely to become periods of hypopnea 
with use of protriptyline. Altematively, increased airway muscle 
tone may lead to a reduced number of severe oxygen desatura-
tions in the presence of obstructive apnea by delaying the 
obstmction until later in the inspiratory phase. Consequently, 
greater residual volume in the lung would cause less rapid 
Table 2 
Means and Standard Deviations of Respiratory 
and Oximetry Measures 
Placebo* Protriptyline* 
Apnea index 44.4 .36.7 
(24.3) (29.2) 
Hypopnea index 42.9 29.0 
(30.4) (16.5) 
Episodes < 85% (index) 5 2 . l t 28.4 
(15.9) (14.1) 
Minutes < 85% (index) 15.5t 8.2 
(12.3) (9.9) 
Low oxygen (oximetry) 37.5 50.3 
(22.7) (19.9) 
Number of apneas 
REM sleep 37.3 21.9 
(26.4) (31.8) 
Non-REM sleep 255.6 235.1 
(154.9) (204.6) 
Mean duration 22.0 22.2 
(seconds) (4.4) (5.6) 
Longest apnea 61.1 57.0 
(seconds) (21.6) (21.0) 
*Means are the first reported data, standard deviations are in parentheses, 
tp < 0.05 
tP < 0.02 
Note: Index values are per hour of tolal sleep time. 
desaturation during an apneic episode. This same phenomenon 
has been offered as a hypothesis to explain why many patients 
in whom UPPP fails have markedly improved oxygenation 
even though their apnea index is unchanged. Surgically widen-
ing the airway and increasing airway muscle tone may be similar 
in this regard. 
Another possibility is that protriptyline may act as a respira-
tory stimulant. Smith et al (7) found a significant increase in 
waking PaO, with protriptyline administration. Our study 
showed a statistical trend toward reduced waking PaCO^ with 
protriptyline. Further study of this hypothesis with a larger sam-
ple size is needed. 
While protriptyline does improve apnea, its effects are incon-
sistent. Based on the present study and prior research, some 
subjects show marked improvement while others are un-
changed. The task of future research is to predict which patients 
Table 3 
Individual Values from Pulmonary Function Tests 
PdO, RiCo, Vc/Co, 
Subiecl Placebo Protriptyline Placebo Protriptyline Placebo Protriptyline 
1 62 — 45 — 
2 73 79 47 41 2.41 3.02 
3 78 74 35 35 2.79 2.13 
4 71 
— 
38 
— 
1.53 2.15 
5 62 84 45 3! 
— — 
6 84 sy 4(1 34 3.12 3.55 
7 76 78 42 41 4.4 4.7 
8 77 78 39 39 3.45 3.18 
Mean 75 80.3 41.3 36.8 2.95 3.12 
SD 7.3 5.3 4.3 4.1 0.97 0.96 
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will benefit from protriptyline therapy in the management of 
their sleep apnea syndrome. Also, research of other medications 
which may increase upper airway muscle tone and/or act as res-
piratory stimulants may lead to effective, safe compounds for 
use in the obstmctive sleep apnea syndrome. 
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